Search the Newsreel

Annexon Inc (ANNX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Annexon Inc (ANNX), focusing on its profitability and balance sheet. It notes the company's current stock price, market capitalization, and indicates that a detailed financial analysis is available within the "Financials" section of the TradingKey platform. …

ANNX|Annexon Inc|Price:5.130|Chg%:-0.090

This article provides a detailed company profile for Annexon Inc (ANNX), a clinical-stage biopharmaceutical company focusing on novel therapies for neuroinflammatory diseases. It outlines their business scope, lead product candidates (ANX005, ANX1502, ANX007), key financial data points such as market capitalization, and lists company …

Annexon Inc (ANNX) Cash Flow

This article provides a detailed cash flow statement for Annexon Inc (ANNX), presenting both quarterly and annual data for operating, investing, and financing activities. It includes key figures like operating cash flow, capital expenditures, net income, and free cash flow, along with year-over-year percentage …

ANNX|Annexon Inc|Price:5.325|Chg%:-0.065

This article provides a detailed company profile for Annexon Inc (ANNX), a clinical-stage biopharmaceutical company focusing on novel therapies for neuroinflammatory diseases. It outlines their business scope, lead product candidates (ANX005, ANX1502, ANX007), key financial data points such as market capitalization, and lists company …

Annexon Inc (ANNX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Annexon Inc (ANNX), focusing on volatility, financial risk, and investment risk. It details various metrics such as Beta vs S&P 500 index, VaR, maximum drawdown, realized volatility, and liquidity indicators like average turnover rate. The data presented …

Annexon Inc (ANNX) Institutional Confidence

This article from TradingKey provides an overview of Annexon Inc.'s (ANNX) institutional confidence, detailing the shareholdings and recent activity of major institutional investors. Firms like Redmile Group, Alerce Investment Management, and BVF Partners L.P. hold significant stakes and have shown varying degrees of change …

Annexon Inc (ANNX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Annexon Inc (ANNX), listing its major shareholders and institutional holdings. It provides updated information on the proportion held by various investment entities, shareholder types, and historical institutional shareholding data. The article also lists Annexon's presence in several …

Annexon Inc (ANNX) Income Statement

Annexon (ANNX) Short Interest & Short Float | Updated Jul 2026

Annexon (ANNX) had a short interest of 29.83 million shares as of July 15, 2026, representing 20.30% of its public float, an increase of 0.75% from the previous report. The short interest ratio is 5.7 days to cover, indicating it would take approximately 5.7 …

TradingKey

This article provides a detailed quarterly balance sheet for Annexon Inc. (ANNX), including data on cash, short-term investments, receivables, prepaid expenses, various asset categories, and liabilities. It also offers FAQs about important balance sheet metrics, the difference between assets, liabilities, and shareholders' equity, and …

Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Annexon Inc (ANNX), detailing analyst ratings and price targets. Based on 12 analysts, the stock has a "Buy" consensus with a target price indicating a potential 170.44% upside. The article also includes information on past and future …

Annexon Price Target Announced at $3.00/Share by Citizens

Citizens has announced a price target of $3.00 per share for Annexon. This update reflects the firm's latest valuation of the company's stock. Investors and market watchers will likely consider this target in their assessment of Annexon's potential performance.

Citizens initiates Annexon stock with underperform on GA trial concerns By Investing.com

Citizens has initiated coverage on Annexon Biosciences (NASDAQ:ANNX) with a Market Underperform rating and a $3.00 price target, citing concerns that Annexon's Phase 3 geographic atrophy trial for vonaprument may not replicate Phase 2 vision benefits. This bearish outlook contrasts with the more optimistic …

H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14

H.C. Wainwright has reiterated its Buy rating on Annexon (ANNX.US) and maintained its target price at $14. This indicates continued confidence from the firm in Annexon's stock performance and future prospects.

Weekly Recap: ARCHER II enrollment completed and 335K options to two hires

Annexon, Inc. (NASDAQ:ANNX) has completed enrollment for its Phase 3 ARCHER II trial for vonaprument, with topline results anticipated in Q4 2026. The company also disclosed that it granted 335,000 inducement options to two new non-executive hires in July 2026. Details on Phase 2 …

H.C. Wainwright reiterates Buy on Annexon stock, $14 target By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $14.00 price target for Annexon Biosciences (NASDAQ:ANNX) following baseline analyses from ARCHER data. The firm highlighted data from the ARCHER study showing 15-letter loss events clustered within a specific BCVA range and noted that the …

Two New Annexon Employees Receive 10-Year Options at $6.50

Annexon (Nasdaq: ANNX) has granted stock options for an aggregate of 335,000 common shares to two new non-executive employees under its 2022 Employment Inducement Award Plan. The options have a ten-year term with an exercise price of $6.50 per share, which was the closing …

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to two new non-executive employees under the terms of its 2022 Employment Inducement Award Plan. These equity awards, approved on July 12, 2026, consist of options to purchase 335,000 shares of common stock with an exercise price …

Needham raises Annexon Biosciences stock price target to $25 on trial

Needham has increased its price target for Annexon Biosciences (NASDAQ:ANNX) to $25 from $11, reiterating a Buy rating, citing the significant upside potential from the current trading price of $5.55. The firm anticipates a positive outcome from the pivotal Phase 3 ARCHER II trial …

Annexon (ANNX) filer Thomas Wiggans eyes 2,000-share NASDAQ stock sale

Thomas Wiggans, a shareholder in Annexon (ANNX), has filed a notice for the proposed sale of 2,000 common shares via Fidelity Brokerage Services LLC on NASDAQ, with an indicated value of $12,630.01. This planned sale follows a previous sale of 1,000 common shares by …

ANNX Maintained by Needham -- Price Target Raised to $25

Needham analyst Joseph Stringer maintained a 'Buy' rating on Annexon (ANNX) and significantly raised the price target from $11.00 to $25.00, reflecting strong confidence in the company's growth potential. Despite a low GF Score of 34/100, primarily due to profitability challenges, the company shows …

Annexon to present data on vonaprument for macular degeneration By Investing.com

Annexon Inc. is set to present Phase 2 ARCHER trial data on its drug candidate, vonaprument, for geographic atrophy at the American Society of Retina Specialists 44th Annual Scientific Meeting. This data will inform patient selection for the ongoing Phase 3 ARCHER II trial, …